Funding
Funding not disclosed
Founders
Product
Problem
Cancer cells often exhibit genomic instability due to defects in DNA damage repair pathways. These inherent vulnerabilities can be exploited to selectively induce cancer cell death. However, current therapeutic strategies may not fully address the complexity of these repair mechanisms.
Solution
SynRx Therapeutics is developing novel anti-cancer agents utilizing a synthetic lethality approach. This strategy targets specific DNA damage repair pathways that are critical for cancer cell survival. By exacerbating these existing vulnerabilities, the company's compounds aim to induce selective cancer cell lethality. Several first-in-class compounds are currently in preclinical development, with a focus on precision targeting to create new therapeutic options for patients.
Target Audience
The primary target audience includes oncologists, clinical researchers, and pharmaceutical companies focused on oncology drug development.
Features
- Development of novel compounds targeting DNA damage repair pathways.
- Application of synthetic lethality principles to induce cancer cell death.
- Preclinical development of first-in-class agents.
- Focus on exploiting genomic instability in cancer cells.
- SY001 targets an undisclosed enzyme critical in DNA damage repair, showing synthetic lethality with BRCA1/2 mutations or homologous recombination defects.
- SY002 targets genomic instability by exacerbating DNA damage repair defects to destabilize replication forks.
- Preclinical data presented at scientific symposia, including AACR and EORTC-NCI-AACR.
- IND clearance received for SYN818, a Polθ inhibitor.